Traws Pharma, Inc.
TRAWNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 | $231,000 |
| Operating income | −$17.9M | −$142.4M | −$20.3M | −$19.6M | −$16.5M | −$25.0M |
| Net income | $9.2M | −$166.5M | −$18.9M | −$19.0M | −$16.2M | −$25.2M |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M | $20.0M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M | $13.8M |
| Equity | −$629,000 | −$31.6M | $10.7M | $28.3M | $46.1M | $6.2M |
| EPS (diluted) | $0.82 | $-35.21 | $-22.57 | $-0.91 | $-0.96 | $-2.17 |
| Shares out. | 5.1M | 21.0M | 21.0M | 20.9M | 236.6M | 167.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −640.7%
- Net margin
- 328.7%
- Return on equity
- −1457.9%
- Return on assets
- 86.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 105.9%
- Debt / equity
- —
- Book value / share
- $-0.12
- Revenue growth (YoY)
- 1134.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -209.84distress
- Accruals / assets
- 257.7%high accruals
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-02Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
- Phase 1Recruitingreadout ~2026-09Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
- Phase 2Not Yet Recruitingreadout ~2026-11Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
- Phase 2Active Not Recruitingreadout ~2026-12This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Squadron Capital Management LlcPassive (13G)May 15, 2026
- Perceptive Advisors LlcPassive (13G)May 15, 2026
- Orbimed Advisors LlcActivist (13D)May 5, 2026
- Ikarian Capital, LlcPassive (13G)Feb 17, 2026
- Adage Capital Management, L.P.Passive (13G)Feb 12, 2026
- Ayrton Capital LlcPassive (13G)Feb 11, 2026
- Chernett JoreyPassive (13G)Jan 16, 2026
- Alyeska Investment Group, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 1.0 | +198.4% |
| Apr 30, 2026 | 560,036 | 1.8 | +38.1% |
| Apr 15, 2026 | 405,599 | 2.0 | -1.5% |
| Mar 31, 2026 | 411,637 | 8.8 | -9.9% |
| Mar 13, 2026 | 456,663 | 4.4 | -12.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 27, 2026
- Other material eventMay 26, 2026
- Results of operations · Regulation FD disclosureMay 15, 2026
- Results of operations · Regulation FD disclosureApr 15, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventApr 15, 2026
- Other material eventFeb 19, 2026
- Other material eventJan 26, 2026
- Other material eventJan 13, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- ARSMay 29, 2026
- DEFA14AMay 29, 2026
- DEF 14AMay 29, 2026
- 8-KFORM 8-KMay 27, 2026
- 8-KFORM 8-KMay 26, 2026
- 424B5May 22, 2026
- PRE 14AFORM PRE14AMay 19, 2026
- EFFECTMay 15, 2026
- 424B3May 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 15, 2026
- 8-KFORM 8-KMay 15, 2026
- S-3FORM S-3May 8, 2026
- SCHEDULE 13D/AMay 5, 2026